COVID 19 drug Paxlovid - Video

Published On 2022-01-01T16:38:02+05:30 | Updated On 1 Jan 2022 4:38 PM IST

Overview

As the number of Omicron cases continues to increase in India and worldwide, recently approved antiviral pills could be a game-changer for the most vulnerable. However, the experts have cautioned that some of these new medications may not be safe for everyone and might require careful monitoring by doctors and pharmacists.

The FDA had recently given approval for Emergency Use Authorisation (EUA) Paxlovid, developed by Pfizer Inc for treating mild-to-moderate Covid-19 in adults and children 12 years and older, who are likely to be at greater risk for severe infection. This came after the fact that in clinical trials Paxlovid was shown to reduce COVID-19-related hospitalization or death from any cause by 89% compared to placebo in patients treated within three days of symptom onset.

Speakers

Dr. Nandita Mohan

BDS, MDS( Pedodontics and Preventive Dentistry)

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751